First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Aurore Perrot, Cyrille Touzeau, Stéphanie Harel et al.|Blood|2025

Cited by 0